GENITOURINARY CANCERS

项目总结(见说明)： 泌尿生殖系癌症方案由来自13个部门的33名研究人员(29名正式成员和4名准成员)组成。该计划由一组基础和临床研究人员组成，共同致力于胃肠道恶性肿瘤的研究和治疗。该计划的具体目标是：1)了解前列腺癌和膀胱癌发生发展的基本机制； 2)支持和促进临床医生和研究科学家在GU癌症方面的合作，建立新的基础、翻译和临床研究计划。在GU癌症计划中有两个主要的研究领域：前列腺癌和膀胱癌。GU计划开发了资助的研究和临床项目，重点是雄激素受体(AR)信号转导 前列腺癌、前列腺癌干细胞、早期前列腺癌的成像、诊断和局部治疗，以及尿路上皮癌的发生。利用这些优势，目前的重点已扩展到成像、焦点治疗、分子风险分层、干细胞生物学/病因学以及前列腺癌种族差异的基于人群的方法。迈克尔·加拉贝迪安博士和萨米尔·塔内贾博士是该项目的共同负责人。自上次竞争以来，资金总额从3,497,189美元增加到5,888,351美元 申请。会员人数从27人增加到33人。这一期间的出版物总数为245份，其中26.9%是方案内出版物，12.2%是方案间出版物，8.2%是方案内和方案间合作出版物。

PROJECT SUMMARY (See instructions): The Genitourinary Cancers Program is composed of 33 investigators (29 Full and 4 Associate members) from 13 Departments. The Program consists of a group of basic and clinical investigators collectively focused upon the study and treatment of GU malignancies. The specific aims of this Program are to: 1) Understandfundamental mechanisms that contribute to development and progression of prostate and bladder cancer; and 2) Support and advance the development of clinicians and research scientists working in a collaborative manner on GU cancers to establish novel basic, translational and clinical research programs. There are two major areas of research focus within the GU Cancer Program: prostate cancer and bladder cancer. The GU Program has developed funded research and clinical programs focused on androgen receptor (AR) signaling in prostate cancer, prostate cancer stem cells, imaging, diagnosis and focal therapy of early stage prostate cancers, as well as urothelial carcinogenesis. Utilizing these strengths, the current focus has expanded into imaging, focal therapy, molecular risk stratification, stem cell biology/etiology, and a population-based approach to racial disparity in prostate cancer. Drs. Michael Garabedian and Samir Taneja are the Co-Leaders for this Program. Total funding increased from $3,497,189 to $5,888,351 since the last competitive application. Membership has increased from 27 to 33. Publications for the period total 245, of which 26.9% are intra-programmatic, 12.2% are inter-programmatic, and 8.2% are both intra- and inter-programmatic collaborations.